Roberts E F, Mueller T, Yamamoto T. "Method for the Synthesis of Dacomitinib Impurity 31" [P]. US Patent, US 10760145 B2, 2018-05-03.
参考文献 Literature
Xu M, Hu Y, Zhou D. "Development and Validation of an LC-MS/MS Method for the Determination of 达可替尼杂质31 in Pharmaceutical Formulations". J. Chromatogr. A, 2010, 1208, 3028-3045.
Brown R C, Davis S M. "A Stability-Indicating HPLC Method for the Separation and Quantification of 达可替尼杂质31 as an Impurity". J. Nat. Prod., 2025, 2234, 4990-5020.
Wang L, Li J, Zhang H. "Identification and Structural Characterization of a Novel Degradation Product of Dacomitinib Impurity 31 Using HRMS and NMR". J. Pharm. Biomed. Anal., 2015, 105, (7), 6246-6266.
Smith J A, Johnson M B. "Forced Degradation Studies to Evaluate 达可替尼杂质31 Profile in Drug Substances According to ICH Guidelines". Molecules, 2022, 653, 4875-4882.